title: Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
abstract: Angiogenesis affects both wound healing and malignant cell growth through nutrients and oxygen. Vascular endothelial growth factor (VEGF) is the most important element involved in this complex process. Inhibition of VEGF influences angiogenesis and may restrict tumor growth and metastatic ability. Modern anti-angiogenic therapy is based on this theory. Bevacizumab is a recombinant humanized monoclonal antibody (immunoglobulin G1) which binds with VEGF-A forming a large molecule. It can not be bound with VEGF tyrosine kinase receptors preventing VEGF-A incorporation; thus its activity is inhibited inducing blockage of VEGF-mediated angiogenesis. Bevacizumab, in combination with chemotherapy or other novel targeted therapeutic agents, is currently used more frequently in clinical practice, mainly for managing advanced colorectal cancer. It is also used for managing other malignancies, such as breast cancer, pancreatic cancer, prostate cancer, non small-cell lung cancer, metastatic renal carcinoma and ovarian tumors. Although it is generally considered a safe treatment, there are reports of some rare side effects which should be taken into account. Recent experiments in rats and mice show promising results with a wider therapeutic range.
authors: Second Surgical Propedeutic Department, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, 54642 Thessaloniki, Greece. pavlidth@med.auth.gr
authors: Efstathios T
authors: ET
authors: Pavlidis
authors: Theodoros E
authors: TE
authors: Pavlidis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Angiogenesis; Anti-angiogenic agents; Avastin; Bevacizumab; Cancer targeted therapy; Colorectal cancer; Vascular endothelial growth factor
references: J Surg Oncol. 2008 Feb 1;97(2):180-5
references: 18095268
references: Oncologist. 2007 Mar;12(3):356-61
references: 17405901
references: Br J Surg. 2006 Dec;93(12):1456-63
references: 17115389
references: Br J Cancer. 2012 May 22;106(11):1718-21
references: 22531628
references: J Chir (Paris). 2010 Jan;147 Suppl 1:S12-7
references: 20172200
references: Med Oncol. 2010 Sep;27(3):807-14
references: 19697164
references: Br J Cancer. 2009 Oct 6;101(7):1033-8
references: 19789532
references: Biologics. 2009;3:429-41
references: 19774210
references: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references: 19720927
references: Anticancer Res. 2012 Jan;32(1):1-12
references: 22213282
references: Ann Oncol. 2010 Jun;21(6):1152-1162
references: 19942597
references: J Clin Oncol. 2007 Oct 20;25(30):4722-9
references: 17947719
references: Am J Health Syst Pharm. 2009 Jun 1;66(11):999-1013
references: 19451611
references: Adv Ther. 2011 Apr;28(4):334-40
references: 21432029
references: Cancer Chemother Pharmacol. 2011 Oct;68(4):951-8
references: 21305289
references: Clin Cancer Res. 2008 Dec 1;14(23):7781-9
references: 19047105
references: Ann Plast Surg. 2009 Jun;62(6):707-9
references: 19461291
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: Radiology. 2008 May;247(2):391-9
references: 18372448
references: Anticancer Drugs. 2010 Aug;21(7):704-7
references: 20517148
references: Drugs. 2008;68(4):487-506
references: 18318567
references: Endocr Relat Cancer. 2009 Sep;16(3):675-702
references: 19525314
references: J Clin Oncol. 2010 Jul 1;28(19):3191-8
references: 20516443
references: Cancer Sci. 2011 Jan;102(1):117-21
references: 21070475
references: Cancer Discov. 2011 Dec;1(7):OF1-2
references: 22586694
references: Ann Oncol. 2010 Feb;21(2):297-304
references: 19940012
references: Oncol Rep. 2008 Sep;20(3):517-23
references: 18695900
references: Endokrynol Pol. 2011;62(5):456-64
references: 22069107
references: Eur Surg Res. 2011;47(1):45-51
references: 21606651
references: Cancer. 2012 Jun 1;118(11):2780-6
references: 22614656
references: Onkologie. 2013;36(6):363-7
references: 23774151
references: Eur J Cancer. 2009 Sep;45(14):2452-61
references: 19643598
references: Otolaryngol Head Neck Surg. 1998 Feb;118(2):178-82
references: 9482548
references: J Exp Clin Cancer Res. 2010 May 26;29:58
references: 20504361
references: BMJ. 2011 Nov 25;343:d7684
references: 22121166
references: Dis Colon Rectum. 2005 Aug;48(8):1632-50
references: 15906130
references: Drug Saf. 2012 Jun 1;35(6):507-18
references: 22612854
references: J Med Econ. 2013 Aug;16(8):1071-81
references: 23777222
references: Crit Rev Oncol Hematol. 2007 Dec;64(3):210-25
references: 17624800
references: Expert Opin Emerg Drugs. 2013 Jun;18(2):137-53
references: 23668489
references: Eur Surg Res. 1998;30(4):273-8
references: 9704754
references: Nat Rev Urol. 2009 Jul;6(7):375-83
references: 19528960
references: World J Gastroenterol. 2009 Jan 28;15(4):449-56
references: 19152449
references: Clin Cancer Res. 2009 Nov 15;15(22):7069-76
references: 19887481
references: J Clin Oncol. 2009 Nov 20;27(33):5499-505
references: 19858399
references: Cancer Chemother Pharmacol. 2010 Sep;66(4):745-53
references: 20033809
references: Invest New Drugs. 2012 Apr;30(2):772-8
references: 21120580
references: J Surg Oncol. 2010 Feb 1;101(2):180-3
references: 19953576
references: Hum Gene Ther. 2010 Apr;21(4):381-96
references: 20163246
references: J Clin Oncol. 2009 Sep 1;27(25):4096-102
references: 19636002
references: Circ Res. 2010 Aug 6;107(3):408-17
references: 20538685
references: J Transl Med. 2010 Feb 10;8:14
references: 20146790
references: Curr Drug Discov Technol. 2009 Jun;6(2):91-102
references: 19519336
references: J Clin Oncol. 2008 Aug 1;26(22):3709-14
references: 18669456
references: Cancer. 2010 Oct 1;116(19):4597-604
references: 20572031
references: Br J Nurs. 2008 Aug 14-Sep 10;17(15):944-9
references: 18983014
references: Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):124-9
references: 20947267
references: Klin Onkol. 2009;22(2):73-6
references: 19522377
references: Surg Today. 2010 Sep;40(9):851-7
references: 20740349
references: J Med Chem. 2010 Jan 14;53(1):452-9
references: 19928864
references: Cancer J. 2007 Sep-Oct;13(5):276-81
references: 17921724
references: Gynecol Oncol. 2009 Sep;114(3):431-6
references: 19524286
references: J Clin Oncol. 2011 Jan 1;29(1):11-6
references: 20940184
references: Br J Cancer. 2010 Feb 2;102(3):495-9
references: 20051952
references: Ann Surg Oncol. 2009 Apr;16(4):856-60
references: 19156464
references: J Clin Oncol. 2009 Feb 10;27(5):740-5
references: 19114704
references: Hum Immunol. 2008 Aug;69(8):510-2
references: 18577409
references: J Clin Pharm Ther. 2007 Feb;32(1):1-14
references: 17286784
references: Aesthetic Plast Surg. 2010 Dec;34(6):796-7
references: 20567970
references: J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
references: 17686822
references: Eur Surg Res. 2000;32(3):177-81
references: 10878459
references: Neuro Oncol. 2010 Mar;12(3):233-42
references: 20167811
references: J Clin Oncol. 2009 Oct 10;27(29):4865-73
references: 19704059
references: Oncol Rep. 2011 Mar;25(3):855-62
references: 21240464
references: Oncologist. 2010;15(11):1179-91
references: 21045188
references: Endokrynol Pol. 2011;62(5):444-55
references: 22069106
references: Int J Cancer. 2011 Feb 15;128(4):920-6
references: 20473899
references: Anticancer Res. 2010 Sep;30(9):3391-5
references: 20944113
references: Eur J Surg Oncol. 2009 Apr;35(4):444-6
references: 18417314
references: BMC Cancer. 2011 Aug 16;11:354
references: 21846341
references: J Surg Oncol. 2005 Sep 1;91(3):173-80
references: 16118771
references: Immunotherapy. 2013 Feb;5(2):113-5
references: 23413901
references: Allergy. 2008 Jul;63(7):945-6
references: 18588566
references: Invest New Drugs. 2012 Aug;30(4):1597-606
references: 21629990
references: Chirurg. 2008 Apr;79(4):351-5
references: 17453167
references: Cancer Biother Radiopharm. 2013 Sep;28(7):501-9
references: 23768086
references: J Clin Oncol. 2003 Jan 1;21(1):60-5
references: 12506171
references: Oncologist. 2010;15(8):845-51
references: 20667969
references: Neoplasia. 2008 May;10(5):511-20
references: 18472968
references: J Surg Res. 2009 Jun 15;154(2):196-202
references: 19329124
references: Can J Surg. 2008 Jun;51(3):E52-3
references: 18682755
references: Angiogenesis. 2010 Mar;13(1):43-58
references: 20229258
references: Biol Pharm Bull. 2011;34(12):1785-8
references: 22130231
references: Cell Commun Adhes. 2011 Oct;18(5):85-103
references: 22017472
references: Int J Colorectal Dis. 2010 Dec;25(12):1465-73
references: 20689957
references: Med Oncol. 2010 Sep;27(3):585-91
references: 19526201
references: Cancer. 2010 Feb 15;116(4 Suppl):1053-8
references: 20127950
references: Acta Med Okayama. 2011 Dec;65(6):353-62
references: 22189475
references: Clin Colorectal Cancer. 2010 Jan;9(1):55-8
references: 20100690
references: Liver Int. 2009 Feb;29(2):284-90
references: 18482274
references: Eur Surg Res. 2006;38(6):540-4
references: 17085940
references: Cancer Res. 2010 May 1;70(9):3483-93
references: 20406973
references: Oncology. 2011;81 Suppl 1:24-9
references: 22212932
references: Rofo. 2010 Feb;182(2):133-9
references: 19862658
references: Oncologist. 2012;17(7):e13-7
references: 22744818